Skip to main content

Oculis Holding AG

OCSAW
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001953530

No open-market purchases or sales by Oculis Holding AG insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $1.16M in total; no superinvestor holds it.

Other share classesOCS

Q3 2024 vs. Q2 2024

How the institutions holding Oculis Holding AG changed between Q2 2024 and Q3 2024.

All holders in Q3 2024All holders in Q2 2024

13F holders of OCSAW: Q2 2024 compared with Q3 2024
MeasureQ2 2024Of which not filed for Q3 2024Q3 2024Change
Holders24121−2
Shares585.0K13.3K547.1K−24.5K (−4.3%)
Value$1.08M$24.7K$1.19M+$132.9K (+12.5%)

1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.

New holders (0)

Institutions that held Oculis Holding AG at the end of Q3 2024 but not at the end of Q2 2024.

None.

Sold out (2)

Institutions that held Oculis Holding AG at the end of Q2 2024 and filed for Q3 2024 without it.

Institutions that sold out of OCSAW in Q3 2024
InstitutionShares, Q2 2024Value, Q2 2024
Kim, LLC11,666$21.6K
UBS Group AG9,652$17.9K

Not filed for Q3 2024 yet (1)

Institutions that held Oculis Holding AG at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding OCSAW in Q2 2024 that haven't filed for Q3 2024
InstitutionShares, Q2 2024Value, Q2 2024
Atalaya Capital Management LP13,333$24.7K